Ocular Therapeutics shares are trading higher after the company announced it received written FDA agreement under a Special Protocol Assessment for its Phase 3 clinical trial for AXPAXLI for the treatment of wet AMD.
Portfolio Pulse from Benzinga Newsdesk
Ocular Therapeutics has received written FDA agreement under a Special Protocol Assessment for its Phase 3 clinical trial for AXPAXLI, a treatment for wet AMD. This news has led to a rise in the company's share prices.
November 01, 2023 | 3:10 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Ocular Therapeutics' stock is trading higher following the FDA's agreement for its Phase 3 clinical trial for AXPAXLI. This could indicate increased investor confidence in the company's potential.
The FDA's agreement for Ocular Therapeutics' Phase 3 clinical trial for AXPAXLI is a significant regulatory milestone for the company. This news is likely to boost investor confidence in the company's potential, leading to a rise in its stock prices.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100